Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8664329 | 1.00 | TSHR (0.46) | TSHRHIF1AFAAHTRPV1OXER1 | |
| SCHEMBL11249699 | 1.00 | TSHR (0.46) | TSHRHIF1AFAAHTRPV1OXER1 | |
| SCHEMBL2486224 | 1.00 | TSHR (0.46) | TSHRHIF1AFAAHTRPV1OXER1 | |
| SCHEMBL835618 | 0.97 | HIF1A (0.47) | TSHRHIF1AFAAHTRPV1OXER1 | |
| SCHEMBL693531 | 0.89 | — | — | |
| SCHEMBL16104757 | 0.80 | TSHR (0.48) | TSHRHIF1AFAAHTRPV1ACLY | |
| SCHEMBL10546638 | 0.80 | TSHR (0.42) | TSHRHIF1AFAAHTRPV1 | |
| SCHEMBL848156 | 0.80 | TSHR (0.42) | TSHRHIF1AFAAHTRPV1 | |
| SCHEMBL19554091 | 0.80 | TSHR (0.42) | TSHRHIF1AFAAHTRPV1 | |
| SCHEMBL285606 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2021252640-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-21 | — | — | US | disclosed |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-21 | — | — | US | disclosed |
| EP-2433940-B9 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| EP-2433940-A1 | SPIROIMIDAZOLONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010126030-A1 | SPIROIMIDAZOLONE DERIVATIVE | 中外製薬株式会社 (JP) | 2010-11-04 | — | — | WO | disclosed |
| US-5476859-A | Inhibiting lentivirus by orally administering derivatives of 1,5-dideoxy-1,5-imino-D-glucitol | PARTIS RICHARD A (US) | 1995-12-19 | — | — | US | disclosed |
| US-5411970-A | Method of inhibiting lentivirus | G. D. SEARLE & CO. (US) | 1995-05-02 | — | — | US | disclosed |
| US-5310745-A | Acylated derivatives of 1,5-dideoxy-1,5-imino-D-glucitol, AIDS | G. D. SEARLE & CO. (US) | 1994-05-10 | — | — | US | disclosed |
| US-5221746-A | Inhibitors of visna virus; treatment of AIDS and ARC | G. D. SEARLE & CO. (US) | 1993-06-22 | — | — | US | disclosed |
| US-5144037-A | Viricides | G. D. SEARLE & CO. (US) | 1992-09-01 | — | — | US | disclosed |
| EP-0494850-A2 | Novel antiviral compounds | G.D. Searle & Co. (US) | 1992-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | TSHR 914/4885HIF1A 3439/4885FAAH 4761/4885 |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | ASNS, SI, NARS1 | TSHR 4589/4885HIF1A 3307/4885FAAH 3546/4885 |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | TSHR 914/4885HIF1A 3439/4885FAAH 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.